[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fLV5Iq-pOYQ1TSOYSGGnWYna8drCU6zrwyNyt4PISBUo":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":42,"rows":49},"Lahey Clinic",[4],60,false,8,3,243293,6,37,[14,16,19,21,23,25,27,29],{"name":15,"count":9},"Hepatocellular Carcinoma",{"name":17,"count":18},"Chronic Sinusitis",2,{"name":20,"count":18},"Lumbar Spondylolisthesis",{"name":22,"count":18},"Degenerative Spondylolisthesis",{"name":24,"count":18},"Bladder Neoplasms",{"name":26,"count":18},"Sinusitis",{"name":28,"count":18},"Pain",{"name":30,"count":18},"Interstitial Lung Disease",[32,37],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06868589","Reducing Pain With Methadone and Ketamine in Liver Transplant","2026-07-01","Methadone",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03696199","Randomized Controlled Trial for Ankle Fracture Pain Control","2026-09-01","Long-Acting Local Anesthesia",[43,44,45,46,47,48],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[50,77,95,113,131,155,173,198,216,241,264,298,323,348,373,396,419,444,480,504,529,556,574,592,610,634,658,681,707,725,749],{"intervention":36,"totalTrials":51,"cells":52},1,{"EARLY_PHASE1":53,"PHASE1":56,"PHASE2":58,"PHASE3":60,"PHASE4":62,"NA":75},{"trials":54,"activeCount":55},[],0,{"trials":57,"activeCount":55},[],{"trials":59,"activeCount":55},[],{"trials":61,"activeCount":55},[],{"trials":63,"activeCount":51,"soonestReadout":35},[64],{"nctId":33,"briefTitle":34,"status":65,"phases":66,"primaryCompletion":35,"completion":40,"start":67,"enrollment":68,"conditions":69,"interventions":71},"ACTIVE_NOT_RECRUITING",[47],"2025-06-30",50,[70],"Liver Transplantation",[36,72,73,74],"ketamine","Hydromorphone","fentanyl",{"trials":76,"activeCount":55},[],{"intervention":72,"totalTrials":51,"cells":78},{"EARLY_PHASE1":79,"PHASE1":81,"PHASE2":83,"PHASE3":85,"PHASE4":87,"NA":93},{"trials":80,"activeCount":55},[],{"trials":82,"activeCount":55},[],{"trials":84,"activeCount":55},[],{"trials":86,"activeCount":55},[],{"trials":88,"activeCount":51,"soonestReadout":35},[89],{"nctId":33,"briefTitle":34,"status":65,"phases":90,"primaryCompletion":35,"completion":40,"start":67,"enrollment":68,"conditions":91,"interventions":92},[47],[70],[36,72,73,74],{"trials":94,"activeCount":55},[],{"intervention":73,"totalTrials":51,"cells":96},{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":101,"PHASE3":103,"PHASE4":105,"NA":111},{"trials":98,"activeCount":55},[],{"trials":100,"activeCount":55},[],{"trials":102,"activeCount":55},[],{"trials":104,"activeCount":55},[],{"trials":106,"activeCount":51,"soonestReadout":35},[107],{"nctId":33,"briefTitle":34,"status":65,"phases":108,"primaryCompletion":35,"completion":40,"start":67,"enrollment":68,"conditions":109,"interventions":110},[47],[70],[36,72,73,74],{"trials":112,"activeCount":55},[],{"intervention":74,"totalTrials":51,"cells":114},{"EARLY_PHASE1":115,"PHASE1":117,"PHASE2":119,"PHASE3":121,"PHASE4":123,"NA":129},{"trials":116,"activeCount":55},[],{"trials":118,"activeCount":55},[],{"trials":120,"activeCount":55},[],{"trials":122,"activeCount":55},[],{"trials":124,"activeCount":51,"soonestReadout":35},[125],{"nctId":33,"briefTitle":34,"status":65,"phases":126,"primaryCompletion":35,"completion":40,"start":67,"enrollment":68,"conditions":127,"interventions":128},[47],[70],[36,72,73,74],{"trials":130,"activeCount":55},[],{"intervention":41,"totalTrials":51,"cells":132},{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":141,"NA":153},{"trials":134,"activeCount":55},[],{"trials":136,"activeCount":55},[],{"trials":138,"activeCount":55},[],{"trials":140,"activeCount":55},[],{"trials":142,"activeCount":51,"soonestReadout":40},[143],{"nctId":38,"briefTitle":39,"status":144,"phases":145,"primaryCompletion":40,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"RECRUITING",[47],"2027-09-01","2020-09-01",70,[150],"Ankle Fractures",[41,152],"Regional Anesthesia",{"trials":154,"activeCount":55},[],{"intervention":152,"totalTrials":51,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":171},{"trials":158,"activeCount":55},[],{"trials":160,"activeCount":55},[],{"trials":162,"activeCount":55},[],{"trials":164,"activeCount":55},[],{"trials":166,"activeCount":51,"soonestReadout":40},[167],{"nctId":38,"briefTitle":39,"status":144,"phases":168,"primaryCompletion":40,"completion":146,"start":147,"enrollment":148,"conditions":169,"interventions":170},[47],[150],[41,152],{"trials":172,"activeCount":55},[],{"intervention":174,"totalTrials":51,"cells":175},"Merogel Nasal Stent and Nasopore Stent",{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":196},{"trials":177,"activeCount":55},[],{"trials":179,"activeCount":55},[],{"trials":181,"activeCount":55},[],{"trials":183,"activeCount":55},[],{"trials":185,"activeCount":55},[186],{"nctId":187,"briefTitle":188,"status":189,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":55,"conditions":193,"interventions":194},"NCT00671541","Nasospore Stent For Use in Enodscopic Sinus Surgery","WITHDRAWN",[47],"2012-02","2006-03",[17],[174,195],"Nasopore Stent and either Gentamycin or Bacitracin",{"trials":197,"activeCount":55},[],{"intervention":195,"totalTrials":51,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":214},{"trials":201,"activeCount":55},[],{"trials":203,"activeCount":55},[],{"trials":205,"activeCount":55},[],{"trials":207,"activeCount":55},[],{"trials":209,"activeCount":55},[210],{"nctId":187,"briefTitle":188,"status":189,"phases":211,"primaryCompletion":191,"completion":191,"start":192,"enrollment":55,"conditions":212,"interventions":213},[47],[17],[174,195],{"trials":215,"activeCount":55},[],{"intervention":217,"totalTrials":51,"cells":218},"0.5% Bupivicaine",{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":239},{"trials":220,"activeCount":55},[],{"trials":222,"activeCount":55},[],{"trials":224,"activeCount":55},[],{"trials":226,"activeCount":55},[],{"trials":228,"activeCount":55},[229],{"nctId":230,"briefTitle":231,"status":232,"phases":233,"primaryCompletion":234,"completion":234,"start":235,"enrollment":148,"conditions":236,"interventions":238},"NCT02055053","Effects of Local Anesthesia on Post-operative Pain During Laparoscopic Inguinal Hernia Repair","COMPLETED",[47],"2019-10-16","2013-08",[237],"Post Operative Pain (Post Laparoscopic Hernia Repair)",[217],{"trials":240,"activeCount":55},[],{"intervention":242,"totalTrials":51,"cells":243},"dexmedetomidine hydrochloride",{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":248,"PHASE3":250,"PHASE4":252,"NA":262},{"trials":245,"activeCount":55},[],{"trials":247,"activeCount":55},[],{"trials":249,"activeCount":55},[],{"trials":251,"activeCount":55},[],{"trials":253,"activeCount":55},[254],{"nctId":255,"briefTitle":256,"status":189,"phases":257,"primaryCompletion":258,"completion":258,"start":259,"enrollment":55,"conditions":260,"interventions":261},"NCT00691886","Safety and Efficacy of Intravenous (IV) Dexmedetomidine During Flexible Bronchoscopy and Endobronchial Ultrasound",[47],"2012-07","2008-04",[28],[242],{"trials":263,"activeCount":55},[],{"intervention":265,"totalTrials":18,"cells":266},"Doxorubin",{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":282,"PHASE4":294,"NA":296},{"trials":268,"activeCount":55},[],{"trials":270,"activeCount":55},[],{"trials":272,"activeCount":55},[273],{"nctId":274,"briefTitle":275,"status":232,"phases":276,"primaryCompletion":277,"completion":277,"start":278,"enrollment":6,"conditions":279,"interventions":281},"NCT02182687","Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant",[45],"2021-10","2014-06",[15,280],"HCC",[265],{"trials":283,"activeCount":55},[284],{"nctId":285,"briefTitle":286,"status":287,"phases":288,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":293},"NCT03960008","Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant","TERMINATED",[46],"2024-02-28","2020-03-01",9,[15,280],[265],{"trials":295,"activeCount":55},[],{"trials":297,"activeCount":55},[],{"intervention":299,"totalTrials":51,"cells":300},"Vesicare",{"EARLY_PHASE1":301,"PHASE1":303,"PHASE2":305,"PHASE3":307,"PHASE4":319,"NA":321},{"trials":302,"activeCount":55},[],{"trials":304,"activeCount":55},[],{"trials":306,"activeCount":55},[],{"trials":308,"activeCount":55},[309],{"nctId":310,"briefTitle":311,"status":287,"phases":312,"primaryCompletion":313,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":318},"NCT00821184","Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder",[46],"2008-09","2006-09",12,[317],"Overactive Bladder",[299],{"trials":320,"activeCount":55},[],{"trials":322,"activeCount":55},[],{"intervention":324,"totalTrials":51,"cells":325},"CoQ10",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":344,"NA":346},{"trials":327,"activeCount":55},[],{"trials":329,"activeCount":55},[],{"trials":331,"activeCount":55},[],{"trials":333,"activeCount":55},[334],{"nctId":335,"briefTitle":336,"status":232,"phases":337,"completion":338,"start":339,"conditions":340,"interventions":343},"NCT00532571","Effects of Coenzyme Q10 in PSP and CBD",[45,46],"2005-09","2004-01",[341,342],"Progressive Supranuclear Palsy","Neurological Disorders",[324],{"trials":345,"activeCount":55},[],{"trials":347,"activeCount":55},[],{"intervention":349,"totalTrials":51,"cells":350},"Anamorelin Hydrochloride",{"EARLY_PHASE1":351,"PHASE1":353,"PHASE2":355,"PHASE3":367,"PHASE4":369,"NA":371},{"trials":352,"activeCount":55},[],{"trials":354,"activeCount":55},[],{"trials":356,"activeCount":55},[357],{"nctId":358,"briefTitle":359,"status":287,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":366},"NCT04844970","Anamorelin Study for Advanced Pancreatic Cancer",[45],"2023-11-07","2023-04-01",4,[365],"Metastatic Pancreatic Cancer",[349],{"trials":368,"activeCount":55},[],{"trials":370,"activeCount":55},[],{"trials":372,"activeCount":55},[],{"intervention":374,"totalTrials":51,"cells":375},"Gemcitabine \u002F Cisplatin \u002F Sorafenib",{"EARLY_PHASE1":376,"PHASE1":378,"PHASE2":380,"PHASE3":390,"PHASE4":392,"NA":394},{"trials":377,"activeCount":55},[],{"trials":379,"activeCount":55},[],{"trials":381,"activeCount":55},[382],{"nctId":383,"briefTitle":384,"status":189,"phases":385,"primaryCompletion":386,"completion":386,"start":387,"enrollment":55,"conditions":388,"interventions":389},"NCT00808145","Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC)",[45],"2014-10","2009-02",[15],[374],{"trials":391,"activeCount":55},[],{"trials":393,"activeCount":55},[],{"trials":395,"activeCount":55},[],{"intervention":397,"totalTrials":51,"cells":398},"Gemcitabine and cisplatin",{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":413,"PHASE4":415,"NA":417},{"trials":400,"activeCount":55},[],{"trials":402,"activeCount":55},[],{"trials":404,"activeCount":55},[405],{"nctId":406,"briefTitle":407,"status":189,"phases":408,"primaryCompletion":409,"completion":409,"start":259,"enrollment":55,"conditions":410,"interventions":412},"NCT00696007","Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer",[45],"2010-04",[411],"Transitional Cell Carcinoma",[397],{"trials":414,"activeCount":55},[],{"trials":416,"activeCount":55},[],{"trials":418,"activeCount":55},[],{"intervention":420,"totalTrials":51,"cells":421},"Femdophilus probiotic",{"EARLY_PHASE1":422,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":423,"activeCount":55},[424],{"nctId":425,"briefTitle":426,"status":189,"phases":427,"primaryCompletion":428,"completion":429,"start":430,"enrollment":55,"conditions":431,"interventions":433},"NCT04077749","Probiotic Bladder Instillation for Prevention of Catheter Associated UTIs in Chronically Catheterized Patients",[43],"2021-06-30","2021-09-15","2021-04-01",[432],"Urinary Tract Infections",[420],{"trials":435,"activeCount":55},[],{"trials":437,"activeCount":55},[],{"trials":439,"activeCount":55},[],{"trials":441,"activeCount":55},[],{"trials":443,"activeCount":55},[],{"intervention":445,"totalTrials":18,"cells":446},"Paclitaxel",{"EARLY_PHASE1":447,"PHASE1":449,"PHASE2":451,"PHASE3":453,"PHASE4":455,"NA":457},{"trials":448,"activeCount":55},[],{"trials":450,"activeCount":55},[],{"trials":452,"activeCount":55},[],{"trials":454,"activeCount":55},[],{"trials":456,"activeCount":55},[],{"trials":458,"activeCount":55},[459,469],{"nctId":460,"briefTitle":461,"status":232,"phases":462,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":468},"NCT04647643","Real-World Safety Analysis of Paclitaxel Devices Used for the Treatment of Peripheral Arterial Disease",[],"2021-12-31","2020-11-20",8000,[467],"Peripheral Arterial Disease",[445],{"nctId":470,"briefTitle":471,"status":232,"phases":472,"primaryCompletion":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":479},"NCT04110288","VQI DELTA Paclitaxel Device Safety Analysis",[],"2019-08-30","2020-04-01","2017-01-01",219483,[478],"Peripheral Vascular Disease",[445],{"intervention":481,"totalTrials":51,"cells":482},"lidocaine hydrochloride",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":493},{"trials":484,"activeCount":55},[],{"trials":486,"activeCount":55},[],{"trials":488,"activeCount":55},[],{"trials":490,"activeCount":55},[],{"trials":492,"activeCount":55},[],{"trials":494,"activeCount":55},[495],{"nctId":496,"briefTitle":497,"status":189,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"enrollment":55,"conditions":502,"interventions":503},"NCT00693043","Pilot Study About Safety and Efficacy of Atomized Intrapleural Lidocaine During Pleuroscopy",[48],"2010-03","2010-05","2008-02",[28],[481],{"intervention":505,"totalTrials":51,"cells":506},"Dexamethasone",{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":517},{"trials":508,"activeCount":55},[],{"trials":510,"activeCount":55},[],{"trials":512,"activeCount":55},[],{"trials":514,"activeCount":55},[],{"trials":516,"activeCount":55},[],{"trials":518,"activeCount":55},[519],{"nctId":520,"briefTitle":521,"status":287,"phases":522,"primaryCompletion":523,"completion":524,"start":525,"enrollment":9,"conditions":526,"interventions":528},"NCT01788475","Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery",[48],"2014-11","2014-11-12","2013-02-22",[527],"Diabetic Macular Edema",[505],{"intervention":530,"totalTrials":51,"cells":531},"Proparacaine Ophthalmic",{"EARLY_PHASE1":532,"PHASE1":534,"PHASE2":536,"PHASE3":538,"PHASE4":540,"NA":542},{"trials":533,"activeCount":55},[],{"trials":535,"activeCount":55},[],{"trials":537,"activeCount":55},[],{"trials":539,"activeCount":55},[],{"trials":541,"activeCount":55},[],{"trials":543,"activeCount":55},[544],{"nctId":545,"briefTitle":546,"status":232,"phases":547,"primaryCompletion":548,"completion":548,"start":313,"enrollment":549,"conditions":550,"interventions":552},"NCT00769392","Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection",[48],"2009-08-12",28,[551],"Macular Degeneration",[530,553,554,555],"Tetracaine Ophthalmic","Lidocaine 4%","Lidocaine 2% Injectable Solution",{"intervention":553,"totalTrials":51,"cells":557},{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":566,"NA":568},{"trials":559,"activeCount":55},[],{"trials":561,"activeCount":55},[],{"trials":563,"activeCount":55},[],{"trials":565,"activeCount":55},[],{"trials":567,"activeCount":55},[],{"trials":569,"activeCount":55},[570],{"nctId":545,"briefTitle":546,"status":232,"phases":571,"primaryCompletion":548,"completion":548,"start":313,"enrollment":549,"conditions":572,"interventions":573},[48],[551],[530,553,554,555],{"intervention":554,"totalTrials":51,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":577,"activeCount":55},[],{"trials":579,"activeCount":55},[],{"trials":581,"activeCount":55},[],{"trials":583,"activeCount":55},[],{"trials":585,"activeCount":55},[],{"trials":587,"activeCount":55},[588],{"nctId":545,"briefTitle":546,"status":232,"phases":589,"primaryCompletion":548,"completion":548,"start":313,"enrollment":549,"conditions":590,"interventions":591},[48],[551],[530,553,554,555],{"intervention":555,"totalTrials":51,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":595,"activeCount":55},[],{"trials":597,"activeCount":55},[],{"trials":599,"activeCount":55},[],{"trials":601,"activeCount":55},[],{"trials":603,"activeCount":55},[],{"trials":605,"activeCount":55},[606],{"nctId":545,"briefTitle":546,"status":232,"phases":607,"primaryCompletion":548,"completion":548,"start":313,"enrollment":549,"conditions":608,"interventions":609},[48],[551],[530,553,554,555],{"intervention":611,"totalTrials":51,"cells":612},"Corticosteroid",{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":614,"activeCount":55},[],{"trials":616,"activeCount":55},[],{"trials":618,"activeCount":55},[],{"trials":620,"activeCount":55},[],{"trials":622,"activeCount":55},[],{"trials":624,"activeCount":55},[625],{"nctId":626,"briefTitle":627,"status":189,"phases":628,"primaryCompletion":629,"completion":629,"start":630,"enrollment":55,"conditions":631,"interventions":633},"NCT03543033","Preoperative Corticosteroid Epidural Injection and Lumbar Decompression Surgery Outcomes",[48],"2020-05-01","2018-09-10",[632],"Lumbar Radiculopathy",[611],{"intervention":635,"totalTrials":51,"cells":636},"3,4-DIAMINOPYRIDINE",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":645,"NA":647},{"trials":638,"activeCount":55},[],{"trials":640,"activeCount":55},[],{"trials":642,"activeCount":55},[],{"trials":644,"activeCount":55},[],{"trials":646,"activeCount":55},[],{"trials":648,"activeCount":55},[649],{"nctId":650,"briefTitle":651,"status":652,"phases":653,"conditions":654,"interventions":657},"NCT00872950","3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)","APPROVED_FOR_MARKETING",[],[655,656],"Lambert-Eaton Myasthenic Syndrome","Congenital Myasthenic Syndrome",[635],{"intervention":659,"totalTrials":51,"cells":660},"Bacitracin",{"EARLY_PHASE1":661,"PHASE1":663,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":671},{"trials":662,"activeCount":55},[],{"trials":664,"activeCount":55},[],{"trials":666,"activeCount":55},[],{"trials":668,"activeCount":55},[],{"trials":670,"activeCount":55},[],{"trials":672,"activeCount":55},[673],{"nctId":674,"briefTitle":675,"status":189,"phases":676,"primaryCompletion":677,"completion":677,"start":678,"enrollment":55,"conditions":679,"interventions":680},"NCT00705354","Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following Endoscopic Sinus Surgery",[48],"2010-10","2009-01",[26,17],[659],{"intervention":682,"totalTrials":51,"cells":683},"Thymoglobulin",{"EARLY_PHASE1":684,"PHASE1":686,"PHASE2":688,"PHASE3":690,"PHASE4":692,"NA":694},{"trials":685,"activeCount":55},[],{"trials":687,"activeCount":55},[],{"trials":689,"activeCount":55},[],{"trials":691,"activeCount":55},[],{"trials":693,"activeCount":55},[],{"trials":695,"activeCount":55},[696],{"nctId":697,"briefTitle":698,"status":232,"phases":699,"primaryCompletion":700,"completion":701,"start":677,"enrollment":702,"conditions":703,"interventions":705},"NCT01280617","Low Dose Thymoglobin in Renal Transplant Patients",[48],"2013-11","2014-01",44,[704],"Acute Renal Failure",[682,706],"Thymoglobulin 0.75mg\u002Fkg dose",{"intervention":706,"totalTrials":51,"cells":708},{"EARLY_PHASE1":709,"PHASE1":711,"PHASE2":713,"PHASE3":715,"PHASE4":717,"NA":719},{"trials":710,"activeCount":55},[],{"trials":712,"activeCount":55},[],{"trials":714,"activeCount":55},[],{"trials":716,"activeCount":55},[],{"trials":718,"activeCount":55},[],{"trials":720,"activeCount":55},[721],{"nctId":697,"briefTitle":698,"status":232,"phases":722,"primaryCompletion":700,"completion":701,"start":677,"enrollment":702,"conditions":723,"interventions":724},[48],[704],[682,706],{"intervention":726,"totalTrials":51,"cells":727},"Ranibizumab",{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":734,"PHASE4":736,"NA":738},{"trials":729,"activeCount":55},[],{"trials":731,"activeCount":55},[],{"trials":733,"activeCount":55},[],{"trials":735,"activeCount":55},[],{"trials":737,"activeCount":55},[],{"trials":739,"activeCount":55},[740],{"nctId":741,"briefTitle":742,"status":189,"phases":743,"primaryCompletion":258,"completion":258,"start":744,"enrollment":55,"conditions":745,"interventions":747},"NCT00726973","Pilot Study Reduced Fluence PDT \u002FVisudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)",[48],"2006-12",[746],"Macular Edema",[726,748],"Ranibizumab monotherapy",{"intervention":748,"totalTrials":51,"cells":750},{"EARLY_PHASE1":751,"PHASE1":753,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":752,"activeCount":55},[],{"trials":754,"activeCount":55},[],{"trials":756,"activeCount":55},[],{"trials":758,"activeCount":55},[],{"trials":760,"activeCount":55},[],{"trials":762,"activeCount":55},[763],{"nctId":741,"briefTitle":742,"status":189,"phases":764,"primaryCompletion":258,"completion":258,"start":744,"enrollment":55,"conditions":765,"interventions":766},[48],[746],[726,748]]